Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 16, 2022

Real-World Outcomes of Addition of Insulin Glargine 300 U/mL to GLP-1 RA Therapy in People With Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study
Diabetes Obes Metab 2022 May 01;[EPub Ahead of Print], TS Bailey, J Gill, M Jones, L Shenoy, C Nicholls, J Westerbacka

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading